Fauci you, Moderna! #DeanSays #SpikeProteins #COVID #Vaccines #Myocarditis #Celia #Purple #Supermodel Fight back with Spike Protein Detox: Now that that’s solved. What do we do about all those pesky little nanobots?

In a historic medical milestone, the world’s first mRNA-based lung cancer vaccine, BNT116, has entered human clinical trials across seven countries. Developed by BioNTech, the same company behind one of the leading COVID-19 vaccines, this breakthrough treatment targets non-small cell lung cancer (NSCLC) — the most common and deadliest type of lung cancer. The vaccine is designed to train the immune system to recognize and destroy cancer cells, offering a more targeted and less toxic alternative to conventional therapies. Currently in Phase 1 clinical trials, the vaccine is being tested on about 130 patients, including participants in the UK, Germany, Spain, and the U.S. The early-stage trials aim to assess safety and immune response, with hopes of preventing cancer recurrence in previously treated patients. If successful, BNT116 could revolutionize how we approach lung cancer — shifting treatment from chemotherapy to a personalized, immune-driven solution. The race toward a cancer vaccine future is officially underway. #LungCancerVaccine #BioNTech #CancerResearch #mRNAtechnology #CancerBreakthrough

Tuberculosis has plagued humanity for centuries, killing more people each year than nearly any other infectious disease. But scientists may have finally turned the tide. A new mRNA vaccine, dubbed mRNACV2, has demonstrated strong effectiveness in preclinical trials—triggering a powerful immune response in mice and dramatically reducing the bacterial load in their lungs. This represents a major leap beyond the current BCG vaccine, which offers limited protection and hasn't changed much since its introduction in 1921. What makes this breakthrough especially significant is the use of mRNA technology—the same approach that powered COVID-19 vaccines. This marks the first time mRNA has shown such promise against a bacterial infection, not just viruses. With human trials now on the horizon, the medical community is hopeful that this could lead to a durable, global solution for TB—a disease that still kills over 1 million people annually despite being preventable and treatable. #mRNAVaccine #TBCure #MedicalBreakthrough #InfectiousDiseases #PublicHealthRevolution

During the COVID-19 pandemic, Dr. Henry Darby, a high school principal from North Charleston High School in South Carolina took on a second job—working overnight shifts at Walmart—not for personal gain, but to support his students in need. Moved by the financial struggles that many of his students’ families were facing, Dr. Darby worked from 10 p.m. to 7 a.m. restocking shelves. He donated all of his earnings to help his students with necessities such as food, housing, and education-related costs. His efforts gained national attention, and Walmart even donated $50,000 to the school in recognition of his commitment. Dr. Darby’s selfless act became a symbol of community leadership, compassion, and dedication to education, drawing admiration from across the country.

Researchers at ETH Zurich have unveiled MenstruAI, a groundbreaking diagnostic platform that transforms menstrual blood into a powerful tool for non-invasive health monitoring. At the heart of the innovation is a smart sanitary pad embedded with a paper-based biosensor, much like a COVID-19 test strip. This sensor detects crucial biomarkers such as: - CRP (C-reactive protein) – a marker for inflammation, - CEA (Carcinoembryonic antigen) – linked to certain cancers, - CA-125 – commonly associated with ovarian cancer and endometriosis. To use the system, individuals take a photo of the used pad with a smartphone. The MenstruAI app, powered by machine learning and image analysis, then interprets color changes in the sensor to deliver personalized health insights. This low-cost, accessible innovation could revolutionize women’s health diagnostics, especially in underserved or remote areas where regular screenings are unavailable. It offers a discreet, private, and empowering alternative to conventional tests.